Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide

P Cochat, A Kassir, S Colon, C Glastre, B Tourniaire… - Pediatric …, 1993 - Springer
P Cochat, A Kassir, S Colon, C Glastre, B Tourniaire, B Parchoux, X Martin, L David
Pediatric Nephrology, 1993Springer
Steroid-resistant nephrotic syndrome (NS) with focal glomerulosclerosis (FGS) and its
recurrence after transplantation are mainly seen in children. The recurrence rate
approximates 30% and the graft loss is about half this. Several therapeutic regimens have
been proposed, giving conflicting results. In an attempt to remove a putative circulating factor
and inhibit its production by lymphocytes, three patients with biopsy-proven FGS in the
native kidney were included in a prospective uncontrolled trial using early plasmaphaeresis …
Abstract
Steroid-resistant nephrotic syndrome (NS) with focal glomerulosclerosis (FGS) and its recurrence after transplantation are mainly seen in children. The recurrence rate approximates 30% and the graft loss is about half this. Several therapeutic regimens have been proposed, giving conflicting results. In an attempt to remove a putative circulating factor and inhibit its production by lymphocytes, three patients with biopsy-proven FGS in the native kidney were included in a prospective uncontrolled trial using early plasmaphaeresis followed by substitutive immunoglobulins in association with methylprednisolone pulses and cyclophosphamide instead of azathioprine over a 2-month period. The patients were girls, aged 6.5, 13.3 and 15.8 years, who received a cadaveric transplant; concomitant immunosuppression included prednisone and cyclosporine A. All three patients exhibited early recurrence of the NS and were treated 5–10 days after the onset of proteinuria. Rapid and sustained remission was achieved in all patients within 12–24 days on therapy. One patient experienced a late acute but steroid-sensitive rejection episode; another suffered from septic ankle arthritis as a complication of reinforced immunosuppression. The latter girl had a second late recurrence of proteinuria that was controlled within 7 weeks. With a 18-to 27-month follow-up, all three patients have normal renal function, normal blood pressure and no proteinuria. We conclude that intensive therapy using plasmaphaeresis, steroid pulses and cyclophosphamide over a 2-month period can induce complete remission in children with early recurrence of NS after transplantation.
Springer